此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

Subset-specific Metabolic Adaptation and Functional Remodeling of Gamma Delta T (γδ T) Cells in Critically Ill ICU Patients: A Single-center, Prospective, Observational Cohort Study.

This prospective observational cohort study investigates the subset-specific metabolic adaptation and functional remodeling of cytotoxic γδT cells in critically ill patients with and without sepsis. Emerging evidence indicates that γδT cells, as a bridge between innate and adaptive immunity, play a critical role in early anti-infection defense during sepsis. However, the functional status and underlying regulatory mechanisms of cytotoxic γδT cells in septic patients remain incompletely understood. Our preliminary single-cell transcriptomic analysis revealed that cytotoxic γδT cells from septic patients exhibit significant alterations in cytotoxicity-associated molecules (GZMB, PRF1, GNLY) and mitochondrial oxidative phosphorylation (OXPHOS) pathway genes, particularly COX6C, which correlates with cytotoxic effector molecule expression. This study aims to systematically characterize the proportion, cytotoxicity, and mitochondrial metabolic function of circulating cytotoxic γδT cells across three cohorts: healthy controls, critically ill non-septic patients, and critically ill septic patients. By integrating flow cytometry, mitochondrial function assays, and functional validation experiments, we seek to elucidate the role of COX6C-mediated mitochondrial metabolic abnormalities in cytotoxic γδT cell dysfunction, providing theoretical basis for understanding immune dysregulation in sepsis and identifying novel therapeutic targets.

研究概览

研究类型

观察性的

注册 (估计的)

105

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Outside of the US
      • Wuhan、Outside of the US、中国、430022
        • 招聘中
        • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

The study population comprises three distinct groups: healthy volunteers, non-septic critically ill patients, and septic critically ill patients admitted to the intensive care unit. Sepsis is defined according to the Sepsis-3 criteria (infection with an acute increase in SOFA score ≥2 points), while critical illness is based on standard ICU admission criteria. All participants must be aged ≥18 years and provide written informed consent (from the participant or a legally authorized representative for those unable to consent). Key exclusion criteria include known immunodeficiency, recent use of T-cell-targeted immunosuppressants or immune checkpoint inhibitors, expected ICU stay <24 hours, pregnancy, active major bleeding, or inability to obtain consent. Consecutive enrollment will take place at the Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with follow-up through 90 days after enrollment.

描述

Inclusion Criteria:

  1. Healthy Control Group (NHC):

    • Age ≥ 18 years.
    • No acute or chronic major diseases.
    • Provide written informed consent.
  2. Non-septic Critical Illness Group (CI-NS):

    • Age ≥ 18 years.
    • Admitted to the ICU and meeting the definition of critical illness.
    • Excluded from sepsis according to the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
    • Written informed consent provided by the participant or legally authorized representative.
  3. Septic Critical Illness Group (CI-Sep):

    • Age ≥ 18 years.
    • Admitted to the ICU and meeting the Sepsis-3 criteria (infection + ΔSOFA ≥ 2 points).
    • Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

  • Age < 18 years.
  • Known immunodeficiency, HIV infection, active hematologic malignancy, or history of hematopoietic stem cell or solid organ transplantation within the past 3 months.
  • Receipt of T-cell-targeted immunosuppressive therapy (e.g., antithymocyte globulin, calcineurin inhibitors, mycophenolate mofetil, methotrexate, or high-dose corticosteroids >1 mg/kg/day prednisone equivalent) before ICU admission or within 24 hours after ICU admission.
  • Use of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies) within the past 6 weeks.
  • Expected ICU stay < 24 hours or imminent risk of death (moribund state).
  • Pregnancy or breastfeeding.
  • Active major bleeding.
  • Inability to obtain informed consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Healthy Controls (NHCs)
Healthy volunteers without acute or chronic major diseases, aged ≥18 years, who have provided written informed consent. Participants undergo a single blood draw and rectal swab collection.
Critically Ill Non-Septic Patients (CI-NS)
Patients admitted to the ICU meeting the criteria for critical illness but without sepsis, as determined by the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points excluded). Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative. Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7). Clinical follow-up extends to 90 days.
Critically Ill Septic Patients (CI-Sep)
Patients admitted to the ICU meeting the Sepsis-3 criteria (infection with ΔSOFA ≥ 2 points). Participants are aged ≥18 years, with informed consent obtained from the patient or legally authorized representative. Blood and rectal swab samples are collected at three time points: within 24 hours of ICU admission (D0), Day 2 (D2), and Day 7 (D7). Clinical follow-up extends to 90 days.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in the Proportion of Cytotoxic γδT Cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) Among Total γδT Cells
大体时间:Day 2 post-ICU admission
Flow cytometric quantification of the frequency of Cytotoxic γδT cells, defined as TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺ cells, as a percentage of total γδT cells (TCRγδ⁺) in peripheral blood. This subset represents the cytotoxic effector population critical for early anti-infection defense.
Day 2 post-ICU admission

次要结果测量

结果测量
措施说明
大体时间
Change in COX6C Expression in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Measurement of COX6C (mitochondrial respiratory chain complex IV subunit) expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at the mRNA level (by single-cell RNA sequencing) and protein level (by flow cytometry).
Day 2 post-ICU admission
Change in Cytotoxic Molecule Expression in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Flow cytometric quantification of the mean fluorescence intensity (MFI) of cytotoxic effector molecules including Granzyme B (GZMB), Perforin (PRF1), and Granulysin (GNLY) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Mitochondrial Mass in Cytotoxic γδT Cell
大体时间:Day 2 post-ICU admission
Flow cytometric quantification of mitochondrial mass using MitoTracker Green FM staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Mitochondrial Membrane Potential (TMRE) in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Flow cytometric quantification of mitochondrial membrane potential using tetramethylrhodamine ethyl ester (TMRE) staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Mitochondrial Membrane Potential (JC-1) in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Flow cytometric quantification of mitochondrial membrane potential using JC-1 dye (red/green fluorescence ratio) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Oxygen Consumption Rate (OCR) in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Measurement of basal oxygen consumption rate reflecting oxidative phosphorylation (OXPHOS) capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Extracellular Acidification Rate (ECAR) in Cytotoxic γδT Cells
大体时间:Day 2 post-ICU admission
Measurement of basal extracellular acidification rate reflecting glycolytic metabolic activity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺).
Day 2 post-ICU admission
Change in Glycolytic Capacity of Cytotoxic γδT Cells at Serial Time Points
大体时间:Day 0, Day 2, and Day 7 post-ICU admission
Longitudinal flow cytometric puromycin-incorporation assay (SCENITH method) to measure glycolytic capacity in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of metabolic flexibility and stress-adaptive glycolytic reprogramming during the course of critical illness.
Day 0, Day 2, and Day 7 post-ICU admission
Change in Mitochondrial ROS Levels in Cytotoxic γδT Cells at Serial Time Points
大体时间:Day 0, Day 2, and Day 7 post-ICU admission
Longitudinal flow cytometric quantification of mitochondrial reactive oxygen species (mitochondrial ROS) levels using MitoSOX Green staining in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, reflecting oxidative stress dynamics.
Day 0, Day 2, and Day 7 post-ICU admission
Change in Cytotoxic γδT Cell Migratory Function
大体时间:Day 2 post-ICU admission
Assessment of Cytotoxic γδT cell (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) chemotactic and migratory capacity using Transwell migration assay.
Day 2 post-ICU admission
Change in Total γδT Cell Proportion at Serial Time Points
大体时间:Day 0, Day 2, and Day 7 post-ICU admission
Longitudinal flow cytometric quantification of the frequency of total γδT cells (TCRγδ⁺) as a percentage of total live CD3⁺ T cells in peripheral blood at Day 0, Day 2, and Day 7 post-ICU admission.
Day 0, Day 2, and Day 7 post-ICU admission
Change in Cytotoxic γδT Cell Proportion at Serial Time Points
大体时间:Day 0, Day 2, and Day 7 post-ICU admission
Longitudinal flow cytometric quantification of the frequency of Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) as a percentage of total γδT cells at Day 0, Day 2, and Day 7 post-ICU admission, to track the temporal evolution of this cell subset.
Day 0, Day 2, and Day 7 post-ICU admission
Change in COX6C Expression in Cytotoxic γδT Cells at Serial Time Points
大体时间:Day 0, Day 2, and Day 7 post-ICU admission
Longitudinal measurement of COX6C expression levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) at Day 0, Day 2, and Day 7 post-ICU admission, to assess the temporal dynamics of mitochondrial metabolic gene expression.
Day 0, Day 2, and Day 7 post-ICU admission
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and APACHE II Score
大体时间:Day 2 post-ICU admission
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with APACHE II (Acute Physiology and Chronic Health Evaluation II) score measured within the first 48 hours of ICU admission.
Day 2 post-ICU admission
Correlation Between Cytotoxic γδT Cell Glycolytic Capacity and SOFA Score
大体时间:Day 2 post-ICU admission
Spearman rank correlation analysis between glycolytic capacity (measured by puromycin incorporation assay at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with SOFA (Sequential Organ Failure Assessment) score measured within the first 48 hours of ICU admission.
Day 2 post-ICU admission
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and vasopressor dose
大体时间:Day 2 post-ICU admission
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with vasopressor dose (reported as norepinephrine equivalent dose, NEE).
Day 2 post-ICU admission
Correlation Between Cytotoxic γδT Cell Metabolic Parameters and plasma lactate levels
大体时间:Day 2 post-ICU admission
Correlation analysis between COX6C expression, glycolytic capacity, and mitochondrial ROS levels in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) with plasma lactate levels.
Day 2 post-ICU admission
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 28-day all-cause mortality
大体时间:Up to 90 days post-discharge
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 28-day all-cause mortality. Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
Up to 90 days post-discharge
Association Between Cytotoxic γδT Cell Glycolytic Capacity and 90-day all-cause mortality
大体时间:Up to 90 days post-discharge
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and 90-day all-cause mortality. Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
Up to 90 days post-discharge
Association Between Cytotoxic γδT Cell Glycolytic Capacity and in-hospital mortality
大体时间:Up to 90 days post-discharge
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and in-hospital mortality. Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
Up to 90 days post-discharge
Association Between Cytotoxic γδT Cell Glycolytic Capacity and ICU mortality
大体时间:Up to 90 days post-discharge
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and ICU mortality. Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
Up to 90 days post-discharge
Association Between Cytotoxic γδT Cell Glycolytic Capacity and hospital length of stay
大体时间:Up to 90 days post-discharge
Analysis of association between glycolytic capacity (measured at Day 2) in Cytotoxic γδT cells (TCRγδ⁺GZMB⁺PRF1⁺GNLY⁺) and hospital length of stay (days). Patients will be stratified by vital status (survivors vs. non-survivors) and by hospital length of stay (above vs. below median) for comparative analysis.
Up to 90 days post-discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月21日

初级完成 (估计的)

2027年4月15日

研究完成 (估计的)

2027年7月15日

研究注册日期

首次提交

2026年6月25日

首先提交符合 QC 标准的

2026年7月1日

首次发布 (实际的)

2026年7月2日

研究记录更新

最后更新发布 (实际的)

2026年9月17日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅